Author details

Full Name

Jianjun Yu

Affiliation

ORCID

Career Start Year

2003

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35304525	Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer.	Scientific Reports	2022
35562750	Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.	Journal of Translational Medicine	2022
35402245	Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer.	Frontiers in Oncology	2022
34471951	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.	Breast Cancer Res Treat	2021
34250422	Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.	JCO Precis Oncol	2021
34504797	Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer.	Frontiers in Oncology	2021
34656931	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.	EBioMedicine	2021
30559381	Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2019
28753431	Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.	Cell	2017
35172518	Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer.	JCO Precision Oncology	2017
26912361	Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.	Science	2016
24831003	Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.	Journal of Biological Chemistry	2014
24474669	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.	Clinical Cancer Research	2014
23615731	Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.	Oncotarget	2013
23818547	Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.	Blood	2013
22179855	Cooperation between Polycomb and androgen receptor during oncogenic transformation.	Genome Res	2012
22460905	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2012
20598134	HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data.	BMC Bioinformatics	2010
20622896	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.	Oncogene	2010
20478527	An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.	Cancer Cell	2010
18929677	Applications of genetic programming in cancer research.	Int J Biochem Cell Biol	2009
18483239	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.	Cancer Res	2008
18579750	TEAD mediates YAP-dependent gene induction and growth control.	Genes Dev	2008
18245462	A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.	Cancer Res	2008
18231641	A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival.	Neoplasia	2008
18077443	Humoral response profiling reveals pathways to prostate cancer progression.	Mol Cell Proteomics	2008
18806826	Repression of E-cadherin by the polycomb group protein EZH2 in cancer.	Oncogene	2008
18538735	The role of SPINK1 in ETS rearrangement-negative prostate cancers.	Cancer Cell	2008
18953438	Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.	Neoplasia	2008
18006806	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.	Cancer Res	2007
17996646	Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.	Cancer Cell	2007
17460773	Feature selection and molecular classification of cancer using genetic programming.	Neoplasia	2007
17804737	Integrative analysis of genomic aberrations associated with prostate cancer progression.	Cancer Res	2007
17409457	Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.	Cancer Res	2007
17356713	Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.	Neoplasia	2007
16286247	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.	Cancer Cell	2005
15548588	Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.	FASEB J	2005
15799970	The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor.	J Biol Chem	2005
16177248	Autoantibody signatures in prostate cancer.	N Engl J Med	2005
15068665	ONCOMINE: a cancer microarray database and integrated data-mining platform.	Neoplasia	2004
15184677	Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.	Proc Natl Acad Sci U S A	2004
12877385	Prostate cancer biomarkers: a current perspective.	Expert Rev Mol Diagn	2003